NCT04439292View on ClinicalTrials.gov

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 12, 2015

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma

Interventions

DRUG

Dabrafenib Mesylate

Given PO

DRUG

Trametinib Dimethyl Sulfoxide

Given PO

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT04439292 - Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) | Biotech Hunter | Biotech Hunter